Patient satisfaction with tildrakizumab treatment in a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe plaque psoriasis

Neal Bhatia; J Gabriel Vasquez; Brad Schenkel; Jayme Heim

doi:10.25251/skin.7.supp.134

Neal Bhatia

Therapeutics Clinical Research

J Gabriel Vasquez

West Michigan Dermatology

Brad Schenkel

Sun Pharmaceutical Industries, Inc.

Jayme Heim

West Michigan Dermatology

Keywords

tildrakizumab, psoriasis, plaque psoriasis, real-world evidence, satisfaction

References

1. Duffin KC, et al. Br J Dermatol. 2014;170(3):672–80.

2. Armstrong AW, et al. JAMA Dermatol. 2013;149(10):1180–85.

3. ILUMYA® (tildrakizumab-asmn) Injection 100 mg/mL. Full prescribing information. Cranbury, NJ; Sun Pharmaceutical Industries, Inc., 2022.

4. Atkinson MJ, et al. Health Qual Life Outcomes. 2004;2:12.

Poster PDF

Published

Mar 13, 2023

DOI https://doi.org/10.25251/skin.7.supp.134

How to Cite

Bhatia, N., Vasquez, J. G., Schenkel, B., & Heim, J. (2023). Patient satisfaction with tildrakizumab treatment in a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe plaque psoriasis. SKIN The Journal of Cutaneous Medicine, 7(2), s134. https://doi.org/10.25251/skin.7.supp.134

Issue

Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®

Section

Posters from 2023 WCH Dermatology Conference: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Todd Schlesinger, Leon Kircik, James Del Rosso, Darrell Rigel, Mark Lebwohl, Brian Berman, April Armstrong, Neal Bhatia, Vishal A. Patel, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Clinician- and Patient-Reported Outcomes with Tirbanibulin 1% Treatment for Actinic Keratosis in Routine Clinical Practice Across the U.S. (PROAK Study) , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 3 (2023): May Issue and Posters from WCH23 & WCM23
Justin Marson, James Del Rosso, Neal Bhatia, Darrell Rigel, Considerations in the Management of Actinic Keratosis: The Importance of Adherence and Persistence to Therapy , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 2 (2021)
Mark Lebwohl, Leon Kircik, Angela Moore, Linda Stein Gold, James Del Rosso, Zoe Draelos, Melinda Gooderham, Lawrence Green, Adelaide Herbert, Kim Papp, Jerry Bagel, Neal Bhatia, Laura Ferris, Terry Jones, Steve Kempers, David Pariser, Paul Yamauchi, Matthew Zirwas, Amy Feng, Patrick Burnett, Robert Higham, David Berk, Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Melinda J. Gooderham, Leon H. Kircik, Matthew Zirwas, Mark Lee, Steven E. Kempers, Zoe D. Draelos, Laura Ferris, Terry M. Jones, Etienne Saint-Cyr Proulx, Robert Bissonnette, Neal Bhatia, Scott T. Guenthner, Robert A. Koppel, Howard Welgus, Charlotte Merritt, Meg Elias, Lynn Navale, Robert C. Higham, Michael Droege, David R. Berk, The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Brian Berman, April Armstrong , Mark Lebwohl, Ayman Grada, Neal Bhatia, Vishal Patel, Darrell Rigel, James Del Rosso, Todd Schlesinger, Leon Kircik, Raidah Salem, Ismail Kasujee, Patient-Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis in Real-world Settings: PROAK Study Protocol , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Todd Schlesinger, Neal Bhatia, Brian Berman, Ayman Grada, Albert Torra, David Cutler, Mark Lebwohl, Favorable Safety Profile of Tirbanibulin Ointment 1% for Actinic Keratosis: Pooled Results from Two Phase III Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Linda Stein Gold, Mark Lebwohl, Neal Bhatia, Douglas DiRuggiero, Abby Jacobson, Radhakrishnan Pillai, Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Jerry Bagel, Linda Stein Gold, James Del Rosso, Neal Bhatia, Sandy Johnson , Paul Yamauchi, Angela Moore, Anna Tallman, Patient Satisfaction with Tapinarof Cream 1% Once Daily for Plaque Psoriasis in a Long-Term Extension Trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Linda Stein Gold, MD, Leon H. Kircik, MD, William Philip Werschler, MD, Hilary Baldwin, MD, Valerie Callender, MD, Lawrence Green, MD, Neil Sadick, MD, Jeffrey L. Sugarman, MD, PhD, Zoe D Draelos, MD, Emil A Tanghetti, MD, Neal Bhatia, MD, Impact of Age or Sex on Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Gel in Participants with Moderate-to-Severe Acne , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 4 (2023): July Issue & Posters from FCPANP 23
Brian Berman, Todd Schlesinger, Neal Bhatia, Ayman Grada, Laura Padulles, Francisco Hernandez, david Cutler, Mark Lebwohl, Complete clearance of actinic keratosis with tirbanibulin ointment 1% is not correlated with the severity of local skin reactions , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)

1 2 3 4 5 6 > >>

Main Article Content

Keywords

References

Article Sidebar

Article Details

Most read articles by the same author(s)